{"abstract":"The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, on behalf of the Centers for Disease Control and Prevention, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to The University of Liverpool, located in Liverpool, UK, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/06/15/2018-12838.html","cfr_references":[],"citation":"83 FR 28002","comment_url":null,"comments_close_on":"2018-07-02","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before July 2, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-12838","effective_on":null,"end_page":28003,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/06/15/2018-12838.xml","html_url":"https://www.federalregister.gov/documents/2018/06/15/2018-12838/prospective-grant-of-exclusive-patent-commercialization-license-streptococcus-pneumonia-psaa-peptide","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-12838?publication_date=2018-06-15","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-06-15/2018-12838/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":136,"last_updated":"2026-10-25 04:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-06-15/pdf/2018-12838.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-12838.pdf?1528980317","publication_date":"2018-06-15","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/06/15/2018-12838.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T06:38:47Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":28002,"subtype":null,"title":"Prospective Grant of Exclusive Patent Commercialization License: Streptococcus Pneumonia PSAA Peptide for Treatment of Sepsis and Infection","toc_doc":"Streptococcus Pneumonia PSAA Peptide for Treatment of Sepsis and Infection","toc_subject":"Prospective Grant of Exclusive Patent Commercialization License:","topics":[],"type":"Notice","volume":83}